Losartan/ja: Difference between revisions

Line 138:

{{See also/ja|Valsartan/ja#recalls|Angiotensin II receptor blocker/ja#recalls}}

~~<div lang="en" dir="ltr" class="mw-content-ltr">~~

2018年11月から2019年9月にかけて、FDAは[[Wikipedia:Sandoz|Sandoz]]、[[Wikipedia:Torrent Pharmaceuticals|Torrent Pharmaceuticals]]、[[:en:Hetero Drugs|Hetero Labs]]、Camber Pharmaceuticals、Legacy Pharmaceutical Packaging、[[Teva Pharmaceutical Industries|Teva Pharmaceuticals]]によるロサルタンを含む錠剤の複数のリコールを発表した、 [[:en:Vivimed Labs|Vivimed Life Sciences]]、およびMacleods Pharmaceutical Limitedは、[[Active ingredient/ja|医薬品有効成分]]（API）から発がん性物質である可能性のある[[N-nitrosodiethylamine/ja|N-ニトロソジエチルアミン]]、N-メチルニトロソ酪酸、N-ニトロソ-N-メチル-4-アミノ酪酸のいずれかが検出されたためである。

~~Between November 2018 and September 2019, the FDA announced multiple recalls of tablets containing losartan by~~ [[Sandoz]], [[Torrent Pharmaceuticals]], [[Hetero Drugs|Hetero Labs]]~~, Camber Pharmaceuticals, Legacy~~ Pharmaceutical ~~Packaging,~~ [[Teva Pharmaceutical Industries|Teva Pharmaceuticals]], [[Vivimed Labs|Vivimed Life Sciences]]~~, and Macleods~~ Pharmaceutical ~~Limited due to detection of one of the possible carcinogens~~ [[N-nitrosodiethylamine]]~~, N~~-~~methylnitrosobutyric acid, or N~~-~~nitroso~~-N-~~methyl~~-4-~~aminobutyric acid in the [[Active ingredient|active pharmaceutical ingredient]] (API).~~

~~</div>~~

@@ Line 138: / Line 138: @@
 {{See also/ja|Valsartan/ja#recalls|Angiotensin II receptor blocker/ja#recalls}}
-<div lang="en" dir="ltr" class="mw-content-ltr">
+年11月から2019年9月にかけて、FDAは[[Wikipedia:Sandoz|Sandoz]]、[[Wikipedia:Torrent Pharmaceuticals|Torrent Pharmaceuticals]]、[[:en:Hetero Drugs|Hetero Labs]]、Camber Pharmaceuticals、Legacy Pharmaceutical Packaging、[[Teva Pharmaceutical Industries|Teva Pharmaceuticals]]によるロサルタンを含む錠剤の複数のリコールを発表した、 [[:en:Vivimed Labs|Vivimed Life Sciences]]、およびMacleods Pharmaceutical Limitedは、[[Active ingredient/ja|医薬品有効成分]]（API）から発がん性物質である可能性のある[[N-nitrosodiethylamine/ja|N-ニトロソジエチルアミン]]、N-メチルニトロソ酪酸、N-ニトロソ-N-メチル-4-アミノ酪酸のいずれかが検出されたためである。
-Between November 2018 and September 2019, the FDA announced multiple recalls of tablets containing losartan by [[Sandoz]], [[Torrent Pharmaceuticals]], [[Hetero Drugs|Hetero Labs]], Camber Pharmaceuticals, Legacy Pharmaceutical Packaging, [[Teva Pharmaceutical Industries|Teva Pharmaceuticals]], [[Vivimed Labs|Vivimed Life Sciences]], and Macleods Pharmaceutical Limited due to detection of one of the possible carcinogens [[N-nitrosodiethylamine]], N-methylnitrosobutyric acid, or N-nitroso-N-methyl-4-aminobutyric acid in the [[Active ingredient|active pharmaceutical ingredient]] (API).
-</div>
 <div lang="en" dir="ltr" class="mw-content-ltr">